Biobran MGN-3 Immunomodulator

Non-toxic arabynoxylan food supplement (or functional food) made from breaking down rice bran with enzymes from the Shitake mushroom. It has been clinically proven to help powerfully enhance depleted immune systems, making it an ideal food supplement for those with immune systems compromised by disease and/or toxic treatments.

Biobran MGN-3 was first developed in Japan in 1992 by Hiroaki Maeda, Director of Research and Development of Daiwa Pharmaceutical Co., Ltd, in Tokyo.

Overview for practitioners

Scientific Overview of Biobran MGN-3 Arabinoxylan by Hiroaki Maeda.

BioBran guide download

BioBran - Rice Bran Arabinoxylan Compound

Download guide

Latest research articles

From Bench to Bedside: The Growing use of Arabinoxylan Rice Bran (MGN-3 /Biobran) in Cancer Immunotherapy

Authors: Mamdooh Ghoneum, Dept of Otolaryngology, Charles Drew University of Medicine and Science, USA

Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial

Authors: Hosny Salama, Eman Medhat, Magda Shaheen, Abdel-Rahman N Zekri, Tarneem Darwish and Mamdooh Ghoneum

Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell — mediated cytotoxicity against neuroblastoma in vitro and in vivo PEER REVIEWED

Authors: Anton Pérez-Martínez, Jaime Valentín, Lucía Fernández, Enrique Hernández-Jiménez, Eduardo López—Collazo, Petra Zerbes, Ellen Schworer, Fernando Nuňéz, Inmaculada Génesis Martín, Hannah Sallis, Miguel Ángel Díaz, Rupert Handgretinger & Matthias Manuel Pfeiffer

MGN-3/BIOBRAN Enhances Generation of Cytotoxic CD8+ T Cells Via Upregulation of DEC-205 Expression on Dendritic Cells PEER REVIEWED

Authors: M. Ghoneum and S. Agrawal

Doctors

Dr. Mandooh Ghoneum Ph.D. (USA, Egypt)

Associate Professor III

Prof. Dr. med. Rupert Handgretinger ( Germany)

Head of University Children’s Hospital - Department of Paediatrics

Ben L. Pfeifer, M.D., Ph.D. (Switzerland)

Professor and Director for Research and Development Aeskulap International, Lucerne, Switzerland

Prof. Dr. habil. Tibor Hajto MD, PhD. ( Hungary)

Department of Immunology and Biotechnology, University Pecs

RNDr. Ján Sedlák, DrSc. (Slovakia)

Director of Cancer Research Institute SAS